PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-17.95%
Cash & equivalents declining -17.95% while Medical - Pharmaceuticals shows -4.89% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-17.95%
Cash + STI yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of -5.48%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
-2.02%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
-1.88%
Inventory growth less than half of Medical - Pharmaceuticals median of 1.32%. Joel Greenblatt might see well-managed stock levels if revenue is fine.
-16.80%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-7.89%
Current assets growth ≥ 1.5x the Medical - Pharmaceuticals median of -1.17%. Joel Greenblatt sees a potential liquidity edge if well allocated.
2.83%
PP&E growth below half of Medical - Pharmaceuticals median of -0.56%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
12.91%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
12.91%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
0.21%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-0.21%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
-0.04%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
2.75%
Below half the Medical - Pharmaceuticals median of -1.45%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
-60.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
-0.52%
0.5-0.75x Medical - Pharmaceuticals median of -0.75%. Guy Spier is cautious about potential underinvestment relative to sector.
-3.50%
Payables growth above 1.5x Medical - Pharmaceuticals median of -0.82%. Jim Chanos might see a warning sign of stressed supplier payments.
230.95%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-44.20%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-44.46%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-1.00%
Below half Medical - Pharmaceuticals median of 0.67%. Joel Greenblatt sees fewer expansions than peers.
-2.95%
Below half Medical - Pharmaceuticals median of 0.92%. Joel Greenblatt sees more conservative short-term leverage than peers.
-13.83%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.42%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-2.92%
Above 1.5x Medical - Pharmaceuticals median of -0.91%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-2.94%
Above 1.5x Medical - Pharmaceuticals median of -0.21%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
1.72%
Below half Medical - Pharmaceuticals median of -1.94%. Jim Chanos suspects poor profitability or large dividend drains.
33.33%
AOCI growth below half of Medical - Pharmaceuticals median -1.32%. Joel Greenblatt sees fewer exposures vs. peers.
-100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
1.65%
Below half Medical - Pharmaceuticals median of -1.68%. Jim Chanos suspects slower net worth growth or losses vs. peers.
-0.52%
0.5-0.75x Medical - Pharmaceuticals median of -0.74%. Guy Spier is cautious about underexpansion vs. peers.
0.21%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
73.31%
Below half Medical - Pharmaceuticals median of -0.14%. Joel Greenblatt sees a stronger deleveraging trend than peers.
30.75%
Above 1.5x Medical - Pharmaceuticals median 6.53%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.